Apatinib for Advanced Radioactive Iodine–Refractory Differentiated Thyroid Cancer
Jan 07, 2022•8 min•Ep. 126
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
On this episode, we're discussing a phase III trial that showed improved progression-free survival with VEGFR2 inhibition in certain patients with thyroid cancer. Then, we'll hear about a report on outcomes of breakthrough COVID-19 infection among fully vaccinated patients with cancer.
Coverage of stories discussed this week on ascopost.com:
Apatinib for Advanced Radioactive Iodine–Refractory Differentiated Thyroid Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
For the best experience, listen in Metacast app for iOS or Android